Market Research Report

A quick peek into the report

1.1.	Introduction to Cancer
1.2.	Cancer Statistics: Incidence, Survival and Mortality
1.2.1.	Important Facts
1.3.	Metastasis and Metastatic Cancer
1.3.1.	Where Cancer Spreads
1.3.1.	Ongoing Research and Treatment of Metastatic Cancer
1.4.	Global Market
1.5.	FDA Approvals of Oncology Drugs
1.6.	Assumptions and Limitation

2.1.	Market Dynamics: Impact Analysis
2.2.	Market Drivers
2.3.	Market Restraints
2.4.	Market Opportunities

3.1.	Introduction
3.2.	Regulatory Scenario
3.3.	Regulatory Designations
3.4.	Patent Landscape

4.1.	Introduction
4.2.	Key Developments and Strategies
4.2.1.	Product Approvals
4.2.2.	Clinical Study
4.2.3.	Agreement, Partnership, Joint Venture and Collaboration
4.2.4	Regulatory Designations
4.2.5.	Acquisition, Product Launches and Others
4.3.	Porter’s Five Forces Analysis
4.3.1.	Bargaining Power of Suppliers
4.3.2.	Bargaining Power of Buyers
4.3.3.	Threat of New Entrant
4.3.4.	Threat of Substitute
4.3.5.	Intensity of Competitive Rivalry
4.4.	Market Share (2014-2017)
4.5.	Pipeline Analysis

5.1.	Overview
5.2.	Breast Cancer
5.2.1.	Breast Cancer: Types, Secondary Sites and Symptoms
5.2.1.1.	Breast Cancer: Molecular Subtypes
5.2.2.	Breast Cancer: Incidence, Mortality and Prevalence
5.2.3	Breast Cancer: Market
5.2.4.	Breast Cancer: Treatment
5.3.	Melanoma
5.3.1.	Melanoma: Types, Secondary Sites and Symptoms
5.3.2.	Melanoma: Incidence, Mortality and Prevalence
5.3.3	Melanoma: Market
5.3.4.	Melanoma: Treatment
5.4.	Prostate Cancer
5.4.1.	Prostate Cancer: Types, Secondary Sites and Symptoms
5.4.2.	Prostate Cancer: Incidence, Mortality and Prevalence
5.4.3.	Prostate Cancer: Market
5.4.4.	Prostate Cancer: Treatment
5.5.	Lung Cancer
5.5.1.	Lung Cancer: Types, Secondary Sites and Symptoms
5.5.2.	Lung Cancer: Incidence, Mortality and Prevalence
5.5.3.	Lung Cancer: Market
5.5.4.	Lung Cancer: Treatment
5.6.	Colorectal Cancer
5.6.1.	Colorectal Cancer: Types, Secondary Sites and Symptoms
5.6.2.	Colorectal Cancer: Incidence, Mortality and Prevalence
5.6.3.	Colorectal Cancer: Market
5.6.4.	Colorectal Cancer: Treatment
5.7.	Other Cancers

6.1.	Overview
6.1.1.	Generic vs. Branded Drugs
6.2.	Role of Branded Medicines in Oncology
6.2.1.	Branded Medicines: Market
6.3.	Role of Generic Medicines in Oncology
6.3.1.	Generic Medicines: Market
6.4.	Sales of Oncology Drugs

7.1.	Overview
7.1.1.	Introduction
7.2.	North America
7.2.1.	The U.S.
7.2.2.	Canada
7.3.	Europe
7.3.1.	Germany
7.3.2.	The U.K.
7.3.3.	France
7.3.4.	Spain
7.3.5.	Italy
7.4.	Asia Pacific
7.4.1.	China
7.4.2.	Japan
7.4.3.	India
7.5.	Latin America
7.5.1.	Brazil
7.5.2.	Mexico
7.5.3.	Argentina
7.6.	Rest of the World

8.1.	AbbVie, Inc.
8.1.1.	Overview
8.1.2.	Overall Product Portfolio
8.1.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.1.3.	Financials
8.1.3.1.	Financial Summary
8.1.4.	Global Presence
8.1.5.	Recent Developments
8.1.6.	SWOT Analysis
8.2.	Amgen, Inc.
8.2.1.	Overview
8.2.2.	Overall Product Portfolio
8.2.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.2.3.	Financials
8.2.3.1.	Financial Summary
8.2.4.	Global Presence
8.2.5.	Recent Developments
8.2.6.	SWOT Analysis
8.3.	AstraZeneca PLC
8.3.1.	Overview
8.3.2.	Overall Product Portfolio
8.2.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.3.3.	Financials
8.3.3.1.	Financial Summary
8.3.4.	Global Presence
8.3.5.	Recent Developments
8.3.6.	SWOT Analysis
8.4.	Bayer AG
8.4.1.	Overview
8.4.2.	Overall Product Portfolio
8.4.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.4.3.	Financials
8.4.3.1.	Financial Summary
8.4.4.	Global Presence
8.4.5.	Recent Developments
8.4.6.	SWOT Analysis
8.5.	Boehringer Ingelheim International GmbH
8.5.1.	Overview
8.5.2.	Overall Product Portfolio
8.5.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.5.3.	Financials
8.5.3.1.	Financial Summary
8.5.4.	Global Presence
8.5.5.	Recent Developments
8.5.6.	SWOT Analysis
8.6.	BRISTOL-MYERS SQUIBB COMPANY
8.6.1.	Overview
8.6.2.	Overall Product Portfolio
8.6.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.6.3.	Financials
8.6.3.1.	Financial Summary
8.6.4.	Global Presence
8.6.5.	Recent Developments
8.6.6.	SWOT Analysis
8.7.	CELGENE CORPORATION
8.7.1.	Overview
8.7.2.	Overall Product Portfolio
8.7.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.7.3.	Financials
8.7.3.1.	Financial Summary
8.7.4.	Global Presence
8.7.5.	Recent Developments
8.7.6.	SWOT Analysis
8.8.	Eli-Lilly and Company
8.8.1.	Overview
8.8.2.	Overall Product Portfolio
8.8.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.8.3.	Financials
8.8.3.1.	Financial Summary
8.8.4.	Global Presence
8.8.5.	Recent Developments
8.8.6.	SWOT Analysis
8.9.	F. Hoffmann-La Roche AG
8.9.1.	Overview
8.9.2.	Overall Product Portfolio
8.9.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.9.3.	Financials
8.9.3.1.	Financial Summary
8.9.4.	Global Presence
8.9.5.	Recent Developments
8.9.6.	SWOT Analysis
8.10.	JOHNSON & JOHNSON
8.10.1.	Overview
8.10.2.	Overall Product Portfolio
8.10.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.10.3.	Financials
8.10.3.1.	Financial Summary
8.10.4.	Global Presence
8.10.5.	Recent Developments
8.10.6.	SWOT Analysis
8.11.	Merck & Co., Inc.
8.11.1.	Overview
8.11.2.	Overall Product Portfolio
8.11.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.11.3.	Financials
8.11.3.1.	Financial Summary
8.11.4.	Global Presence
8.11.5.	Recent Developments
8.11.6.	SWOT Analysis
8.12.	Novartis AG
8.12.1.	Overview
8.12.2.	Overall Product Portfolio
8.12.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.12.3.	Financials
8.12.3.1.	Financial Summary
8.12.4.	Global Presence
8.12.5.	Recent Developments
8.12.6.	SWOT Analysis
8.13.	Pfizer, Inc.
8.13.1.	Overview
8.13.2.	Overall Product Portfolio
8.13.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.13.3.	Financials
8.13.3.1.	Financial Summary
8.13.4.	Global Presence
8.13.5.	Recent Developments
8.13.6.	SWOT Analysis
8.14.	SANOFI
8.14.1.	Overview
8.14.2.	Overall Product Portfolio
8.14.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.14.3.	Financials
8.14.3.1.	Financial Summary
8.14.4.	Global Presence
8.14.5.	Recent Developments
8.14.6.	SWOT Analysis
8.15.	Takeda Pharmaceutical Company Limited
8.15.1.	Overview
8.15.2.	Overall Product Portfolio
8.15.2.1.	Product Offerings for Metastatic Cancer Treatment Market
8.15.3.	Financials
8.15.3.1.	Financial Summary
8.15.4.	Global Presence
8.15.5.	Recent Developments
8.15.6.	SWOT Analysis
8.16.	bluebird bio, Inc.
8.16.1.	Overview
8.16.2.	Product Offerings for Metastatic Cancer Treatment Market
8.17.	Clovis Oncology, Inc.
8.17.1.	Overview
8.17.2.	Product Offerings for Metastatic Cancer Treatment Market
8.18.	IDERA PHARMACEUTICALS, INC.
8.18.1.	Overview
8.18.2.	Product Offerings for Metastatic Cancer Treatment Market
8.19.	eTheRNA immunotherapies NV
8.19.1.	Overview
8.19.2.	Product Offerings for Metastatic Cancer Treatment Market

9.1.	Scope of the Report
9.2.	Global Metastatic Cancer Treatment Market Segmentation
9.3.	Research Methodology
9.3.1.	Primary Research
9.3.2.	Secondary Research
9.3.3.	Key Data Points from Primary Sources
9.3.4.	Key Data Points from Secondary Sources
9.3.5.	Data Triangulation
9.3.6.	Top-Down Approach (Segment Wise Analysis)
9.3.7.	Bottom-Up Approach (Segmental Analysis)
9.4.	Assumptions and Limitations
9.5.	Data and Prediction Modelling

10.1.	Recent Key Developments and Strategies
10.2.	Product Mapping
10.3.	Cancer Data Sheet

Table 1	Total Regional Geriatric Population by Region (%), 2015 and 2030
Table 2	Impact of Market Drivers
Table 3	Impact of Market Restraints
Table 4	Market Share (2014-2017)
Table 1.1	Estimated New Cases and Estimated Deaths in 2018 as per American Cancer Society
Table 1.2	GLOBOCAN Data as of 2012
Table 1.3	Common sites of Metastasis for Cancers
Table 1.4	Common Classes of Drugs Under Different Cancer Therapies
Table 1.5	Recent FDA Approvals of Oncology Drugs
Table 2.1	Impact of Market Drivers
Table 2.2	Impact of Market Restraints
Table 2.3	Comparison of R&D Expense 2017 and 2016
Table 2.4	Recent Approval of Metastatic Cancer Drugs
Table 2.5	Side Effects Caused by common Metastatic Cancer Drugs
Table 3.1	Regulatory Scenario Across the World
Table 3.2	Regulatory Designations Across The World
Table 3.3	Patent Landscape
Table 4.1	Factors Affecting the Bargaining Power of Suppliers
Table 4.2	Factors Affecting the Bargaining Power of Buyer
Table 4.3	Factors Affecting Threat of New Entrant
Table 4.4	Factors Affecting the Threat of Substitute
Table 4.5	Factors Affecting the Intensity of Competitive Rivalry
Table 4.6	Market Share of Key Players (2014-2017)
Table 4.7	Pipeline Analysis of Metastatic Cancer Treatment Drugs
Table 5.1	Estimated Incidence, Mortality, and Prevalence of Breast Cancer Worldwide in 2012
Table 5.2	Estimated Incidence and Mortality of Melanoma Worldwide in 2012
Table 5.3	Estimated Incidence, Mortality and Prevalence of Prostate Cancer Worldwide in 2012
Table 5.4	Estimated Incidence, Mortality and Prevalence of Lung Cancer (for both sexes) Worldwide in 2012
Table 5.5	Estimated Incidence, Mortality and Prevalence of Colorectal Cancer (for both sexes) Worldwide in 2012
Table 5.6	Estimated Incidence, Mortality and Prevalence of Different Cancer (for both sexes) Worldwide in 2012
Table 5.7	List of Companies and Drugs for Various Therapeutic Indication
Table 6.1	List of Common Brand-name Drugs used to treat Metastatic Cancer
Table 6.2	List of Common Generic Drugs used to treat Metastatic Cancer
Table 6.3	Sales of Oncology Drugs
Table 7.1	State-wise distribution of Cancer in India
Table 8.1	List of Tier 1 and Tier 2 Companies
Table 8.2	AbbVie Inc.: Recent Developments
Table 8.3	Amgen, Inc.: Recent Developments
Table 8.4	AstraZeneca PLC: Recent Developments
Table 8.5	Bayer AG: Recent Developments
Table 8.6	Boehringer Ingelheim International GmbH: Recent Developments
Table 8.7	BRISTOL-MYERS SQUIBB COMPANY: Recent Developments
Table 8.8	CELGENE CORPORATION: Recent Developments
Table 8.9	Eli-Lilly and Company: Recent Developments
Table 8.10	F. Hoffmann-La Roche AG: Recent Developments
Table 8.11	JOHNSON & JOHNSON: Recent Developments
Table 8.12	Merck & Co.,Inc. : Recent Developments
Table 8.13	Novartis AG: Recent Developments
Table 8.14	Pfizer, Inc.: Recent Developments
Table 8.15	SANOFI: Recent Developments
Table 8.16	Takeda Pharmaceutical Company Limited: Recent Developments

Figure 1	Common Treatments of Cancer
Figure 2	Global Metastatic Cancer Treatment Market ($Million)
Figure 3	Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2017
Figure 4	Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2025
Figure 5	Global Metastatic Cancer Treatment Market by Products, 2017
Figure 6	Global Metastatic Cancer Treatment Market By Products, 2025
Figure 7	Global Metastatic Cancer Treatment Market by Region, 2017
Figure 8	Global Injectable Drug Delivery Market by Region, 2025
Figure 1.1	Causes of Cancer
Figure 1.2	Common Mechanism of Metastasis
Figure 1.3	Types of Metastatic Cancer (based on how far it has spread)
Figure 1.4	Global Metastatic Cancer Treatment Market, 2016-2025 ($ Million)
Figure 2.1	Market Dynamics: Drivers, Restraints & Opportunities
Figure 2.2	Targeted Therapies Designed for Different Cancer Types
Figure 3.1	Industry Insights (January 2014-February 2018)
Figure 4.1	Competitive Landscape (January 2014-February 2018)
Figure 4.2	Share of Key Developments and Strategies(January 2014 to March 2018)
Figure 4.3	Product Approvals by Companies
Figure 4.4	Clinical Study, by Companies
Figure 4.5	Product Approvals by Companies
Figure 4.6	Porter’s Five Forces Analysis
Figure 5.1	Types of Metastatic Cancer by Therapeutic Indication
Figure 5.2	Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2014-2025 ($Million)
Figure 5.3	Signs and Symptoms of Metastatic Breast Cancer
Figure 5.4	Common Molecular Subtypes of Breast Cancer
Figure 5.5	Global Metastatic Cancer Treatment Market by Breast Cancer, 2014-2025 ($ Million)
Figure 5.6	List of Common Metastatic Breast Cancer Drugs
Figure 5.7	Signs and Symptoms of Metastatic Melanoma
Figure 5.8	Global Metastatic Cancer Treatment Market by Melanoma Cancer, 2014-2025 ($ Million)
Figure 5.9	List of Common Metastatic Melanoma Cancer Drugs
Figure 5.10	Signs and Symptoms of Metastatic Prostate Cancer
Figure 5.11	Global Metastatic Cancer Treatment Market by Prostate Cancer, 2014-2025 ($ Million)
Figure 5.12	List of Common Metastatic Prostate Cancer Drugs
Figure 5.13	Signs and Symptoms of Metastatic Lung Cancer
Figure 5.14	Global Metastatic Cancer Treatment Market by NSCLC, 2014-2025 ($ Million)
Figure 5.15	List of Common Metastatic Lung Cancer Drugs
Figure 5.16	Signs and Symptoms of Metastatic Colorectal Cancer
Figure 5.17	Global Metastatic Cancer Treatment Market by Colorectal Cancer, 2014-2025 ($ Million)
Figure 5.18	List of Common Metastatic Colorectal Cancer Drugs
Figure 5.19	Global Metastatic Cancer Treatment Market by Other Cancers, 2014-2025 ($ Million)
Figure 6.1	Classification of Anti-Cancer Drugs by Pharma Class
Figure 6.2	Global Metastatic Cancer Treatment Market by Branded Medicines, 2014-2025 ($ Million)
Figure 6.3	Global Metastatic Cancer Treatment Market by Generic Medicines, 2014-2025 ($ Million)
Figure 7.1	Global Metastatic Cancer Treatment Market by Region, 2014-2025 ($Million)
Figure 7.2	North America Metastatic Cancer Treatment Market, 2014-2025 ($Million)
Figure 7.3	North America Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million)
Figure 7.4	Cancer Patient Data by Cancers Type in the U.S. (2016)
Figure 7.5	Cancer Patient Data by Cancers Type in Canada (2016)
Figure 7.6	The U.S. Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.7	Canada Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.8	Europe Metastatic Cancer Treatment Market, 2014-2025 ($Million)
Figure 7.9	Europe Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million)
Figure 7.10	Cancer Patient Data by Cancers Type in Germany (2016)
Figure 7.11	Cancer Patient Data by Cancers Type in France (2016)
Figure 7.12	Cancer Patient Data by Cancers Type in Italy (2016)
Figure 7.13	France Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.14	Germany Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.15	Italy Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.16	Netherland Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.17	Switzerland Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.18	The U.K. Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.19	Spain Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.20	Sweden Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.21	Austria Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.22	Belgium Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.23	Denmark Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.24	Finland Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.25	Poland Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.26	Russia Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.27	Ireland Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.28	Rest of Europe Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.29	Asia Pacific Metastatic Cancer Treatment Market, 2014-2025 ($Million)
Figure 7.30	Asia Pacific Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million)
Figure 7.31	Cancer Patient Data by Cancers Type in China (2016)
Figure 7.32	Cancer Patient Data by Cancers Type in Japan (2016)
Figure 7.33	Cancer Patient Data by Cancers Type in India (2016)
Figure 7.35	China Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.36	Japan Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.37	India Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.38	South Korea Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.39	Australia Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.40	Bangladesh Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.41	Malaysia Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.42	New Zealand Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.43	Rest of Asia Pacific Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.44	Latin America Metastatic Cancer Treatment Market, 2014-2025 ($Million)
Figure 7.45	Latin America Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million)
Figure 7.46	Brazil Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.47	Mexico Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.48	Argentina Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.49	Rest of Latin America Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.50	Rest of the World (RoW) Metastatic Cancer Treatment Market, 2014-2025 ($Million)
Figure 7.51	Rest of the World (RoW) Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million)
Figure 7.52	Saudi Arabia Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.53	UAE Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.54	South Africa Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.55	Israel Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 7.56	Other Metastatic Cancer Treatment Market, 2014-2025 ($million)
Figure 8.1	Contribution of Various companies
Figure 8.2	AbbVie Inc.: Overall Product Portfolio
Figure 8.3	AbbVie Inc.: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.4	AbbVie Inc.: Overall Financials (2014-2017)
Figure 8.5	AbbVie Inc.: Revenue by Geography (2014-2017)
Figure 8.6	AbbVie Inc.: Global Presence
Figure 8.7	AbbVie Inc.: SWOT Analysis
Figure 8.8	Amgen, Inc.: Overall Product Portfolio
Figure 8.9	Amgen, Inc.: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.10	Amgen, Inc. : Overall Financials (2014-2017)
Figure 8.11	Amgen, Inc. : Revenue by Geography (2014-2017)
Figure 8.12	Amgen, Inc.: Global Presence
Figure 8.13	Amgen, Inc. : SWOT Analysis
Figure 8.14	AstraZeneca PLC: Overall Product Portfolio
Figure 8.15	AstraZeneca PLC: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.16	AstraZeneca PLC: Overall Financials (2014-2017)
Figure 8.17	AstraZeneca PLC: Revenue by Product Sales (2014-2017)
Figure 8.18	AstraZeneca PLC: Revenue by Geography (2014-2017)
Figure 8.19	AstraZeneca PLC: Global Presence
Figure 8.20	AstraZeneca PLC: SWOT Analysis
Figure 8.21	Bayer AG: Overall Product Portfolio
Figure 8.22	Bayer AG: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.23	Bayer AG: Overall Financials (2014-2017)
Figure 8.24	Bayer AG: Revenue by Geography (2014-2017)
Figure 8.25	Bayer AG: Revenue by Business Segment (2014-2015)
Figure 8.26	Bayer AG: Revenue by Buisness Segment (2016-2017)
Figure 8.27	Bayer AG: Global Presence
Figure 8.28	Bayer AG: SWOT Analysis
Figure 8.29	Boehringer Ingelheim International GmbH: Overall Product Portfolio
Figure 8.30	Boehringer Ingelheim International GmbH: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.31	Boehringer Ingelheim International GmbH: Overall Financials (2014-2017)
Figure 8.32	Boehringer Ingelheim International GmbH: Revenue by Geography (2014-2017)
Figure 8.33	Boehringer Ingelheim International GmbH: Revenue by Business Segment (2014-2015)
Figure 8.34	Boehringer Ingelheim International GmbH: Revenue by Buisness Segment (2016-2017)
Figure 8.35	Boehringer Ingelheim International GmbH: Global Presence
Figure 8.36	Boehringer Ingelheim International GmbH: SWOT Analysis
Figure 8.37	BRISTOL-MYERS SQUIBB COMPANY: Overall Product Portfolio
Figure 8.38	BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.39	BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2017)
Figure 8.40	BRISTOL-MYERS SQUIBB COMPANY: Revenue by Geography (2014-2017)
Figure 8.41	BRISTOL-MYERS SQUIBB COMPANY: Global Presence
Figure 8.42	BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis
Figure 8.43	CELGENE CORPORATION: Overall Product Portfolio
Figure 8.44	CELGENE CORPORATION: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.45	CELGENE CORPORATION: Overall Financials (2014-2017)
Figure 8.46	CELGENE CORPORATION: Revenue by Geography (2014-2017)
Figure 8.47	CELGENE CORPORATION: Global Presence
Figure 8.48	CELGENE CORPORATION: SWOT Analysis
Figure 8.49	Eli-Lilly and Company: Overall Product Portfolio
Figure 8.50	Eli-Lilly and Company: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.51	Eli-Lilly and Company: Overall Financials (2014-2017)
Figure 8.52	Eli-Lilly and Company: Revenue by Business segment (2014-2017)
Figure 8.53	Eli-Lilly and Company: Revenue by Geography (2014-2017)
Figure 8.54	Eli-Lilly and Company: Global Presence
Figure 8.55	Eli-Lilly and Company: SWOT Analysis
Figure 8.56	F. Hoffmann-La Roche AG: Overall Product Portfolio
Figure 8.57	F. Hoffmann-La Roche AG: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.58	F. Hoffmann-La Roche AG: Overall Financials (2014-2017)
Figure 8.59	F. Hoffmann-La Roche AG: Product Sales by Region (2014-2017)
Figure 8.60	F. Hoffmann-La Roche AG: Revenue by Division (2014-2017)
Figure 8.61	F. Hoffmann-La Roche AG: Revenue by Pharmaceutical Sub-Segment (2014-2017)
Figure 8.62	F. Hoffmann-La Roche AG: Global Presence
Figure 8.63	F. Hoffmann-La Roche AG: SWOT Analysis
Figure 8.64	JOHNSON & JOHNSON: Overall Product Portfolio
Figure 8.65	JOHNSON & JOHNSON: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.66	JOHNSON & JOHNSON: Overall Financials (2014-2017)
Figure 8.67	JOHNSON & JOHNSON: Revenue by Business segment (2014-2017)
Figure 8.68	JOHNSON & JOHNSON: Revenue by Geography (2014-2017)
Figure 8.69	JOHNSON & JOHNSON: Global Presence
Figure 8.70	JOHNSON & JOHNSON: SWOT Analysis
Figure 8.71	Merck & Co., Inc.: Overall Product Portfolio
Figure 8.72	Merck & Co., Inc.: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.73	Merck & Co., Inc.: Overall Financials (2014-2017)
Figure 8.74	Merck & Co., Inc.: Revenue by Business segment (2014-2017)
Figure 8.75	Merck & Co., Inc.: Revenue by Geography (2014-2017)
Figure 8.76	Merck & Co., Inc.: Global Presence
Figure 8.77	Merck & Co., Inc.: SWOT Analysis
Figure 8.78	Novartis AG: Overall Product Portfolio
Figure 8.79	Novartis AG: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.80	Novartis AG: Overall Financials (2014-2017)
Figure 8.81	Novartis AG: Revenue by Geography (2014-2017)
Figure 8.82	Novartis AG: Revenue by Business Segment (2014-2015)
Figure 8.83	Novartis AG: Revenue by Buisness Segment (2016-2017)
Figure 8.84	Novartis AG: Global Presence
Figure 8.85	Novartis AG: SWOT Analysis
Figure 8.86	Pfizer, Inc.: Overall Product Portfolio
Figure 8.87	Pfizer, Inc.: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.88	Pfizer, Inc.: Overall Financials (2014-2017)
Figure 8.89	Pfizer, Inc.: Revenue by Business segment (2014-2017)
Figure 8.90	Pfizer, Inc.: Revenue by Geography (2014-2017)
Figure 8.91	Pfizer, Inc.: Global Presence
Figure 8.92	Pfizer, Inc.: SWOT Analysis
Figure 8.93	SANOFI: Overall Product Portfolio
Figure 8.94	SANOFI: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.95	SANOFI: Overall Financials (2014-2017)
Figure 8.96	SANOFI: Revenue by Business Segment (2014-2015)
Figure 8.97	SANOFI: Revenue by Business Segment (2016-2017)
Figure 8.98	SANOFI: Revenue by Geography (2014-2015)
Figure 8.99	SANOFI: Revenue by Geography (2016-2017)
Figure 8.100	SANOFI: Global Presence
Figure 8.101	SANOFI: SWOT Analysis
Figure 8.102	Takeda Pharmaceutical Company Limited: Overall Product Portfolio
Figure 8.103	Takeda Pharmaceutical Company Limited: Product Portfolio for Metastatic Cancer Treatment Market
Figure 8.104	Takeda Pharmaceutical Company Limited: Overall Financials (2014-2017)
Figure 8.105	Takeda Pharmaceutical Company Limited: Revenue by Business segment (2014-2017)
Figure 8.106	Takeda Pharmaceutical Company Limited: Revenue by Geography (2014-2017)
Figure 8.107	Takeda Pharmaceutical Company Limited: Global Presence
Figure 8.108	Takeda Pharmaceutical Company Limited: SWOT Analysis
Figure 8.109	bluebird bio, Inc.: Product Pipeline for Cancer Treatment Market
Figure 8.110	Clovis Oncology, Inc.: Product Pipeline for Cancer Treatment Market
Figure 8.111	IDERA PHARMACEUTICALS, INC.: Product Pipeline for Cancer Treatment Market
Figure 8.112	eTheRNA immunotherapies NV: Product Pipeline for Cancer Treatment Market
Figure 9.1	Global Metastatic Cancer Treatment Market Segmentation
Figure 9.2	Considered Factors for Data Prediction & Modeling

Report Description

The healthcare industry is a multi-billion dollars market consisting of various verticals aimed at improving patient lives. With increase in research and developmental activities, technological advancements are being made to make patient services convenient and affordable. Cancer represents one of the major concern of the global healthcare industry, as it is the second leading cause of death all around the world (according to WHO). Cancer statistics has a major impact on society across the world and accounts for almost 70% of death in low- and middle- income countries. As per GLOBOCAN data, there were almost 14 million cancer cases globally in 2012, which claimed almost 8 million patient lives. As a result, enormous scientific innovation is taking place in the field of oncology for the development of novel oncology medicines that are significantly propelling the growth of metastatic cancer treatment market. Metastatic cancer, represents the advanced form of cancer, which occurs when the cancer cells starts spreading from the primary site of origin to different parts of the body. Treatment of metastatic cancer is often not curable and is mainly focussed on providing palliative care. Several companies are investing into oncology market and are making strenuous effort for the delivery of cost-effective cancer treatment drugs used in chemotherapy, radiation therapy, and hormone therapy. Patients all over the world are looking forward for advanced cancer therapy drugs to arrest their condition, which is turn is increasing the adoption rate of the metastatic cancer treatment drugs.

The metastatic cancer treatment market consists of products, such as generic medicines and branded medicines, used in the treatment of metastatic cancer. The market analysis includes an in-depth examination of the key ecosystem players, key strategies, and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges) and industry analysis. The market has been classified based on different therapeutic indications, such as breast cancer, melanoma, colorectal cancer, lung cancer, prostate cancer, and others. Geographically, the market can be segmented into five distinct regions including, North America, Europe, Asia-Pacific, Latin America, and Rest of the World.

The purpose of the study is to gain a holistic view of the global metastatic cancer treatment market in terms of various factors influencing it such as key market trends, competitive and regulatory aspects of the market, scientific innovations into oncology fields, etc. The scope of the report is centered upon conducting a detailed study of the solutions allied with metastatic cancer treatment market, which involves drugs used in different therapeutic applications of cancer treatment such as chemotherapy, hormone therapy, and immunotherapy, among others. The global metastatic cancer treatment market is segmented into three different parts: ‘by products’, ‘by therapeutic indication’, and ‘by region’. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global metastatic cancer treatment market, and assesses the factors governing the same. Opportunity matrix and detailed product mapping have been included in the report. The market by region has been further sub-segmented in various countries, and in each sub-segment the key market trends, list of the key players, and recent developments, have been discussed.

The key players that have been contributing significantly include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi and Takeda Pharmaceutical Company Limited, among others.

Key Questions Answered in this Report

The answers t?o the following key questions can be derived from this report:

• What are the major market drivers, restraints, and opportunities in the global metastatic cancer treatment market?
• What are the market shares of the leading segments, and sub-segments of the global metastatic cancer treatment market in 2017 and what will be its value in 2026?
• How will each segment of the global metastatic cancer treatment market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2026?
• What are the influencing factors that may affect the market share of the key players?
• What are the key developmental strategies implemented by the key players to stand out in this market?
• What are the major Regulatory Authorities/ Associations/ Consortiums affecting the metastatic cancer treatment market and what are the main designations facilitating development and approval of cancer drugs?
• Which are the companies holding patent rights for the metastatic cancer treatment drugs and what patent landscape exist in the market?
• Which product segment is expected to register the highest CAGR for the global metastatic cancer treatment market?
• How has the market been segmented based on therapeutic indication? Which therapeutic indication segment has the largest share, and fastest growth rate in the global metastatic cancer treatment market?
• Which geographical region will contribute to the highest sales of the metastatic cancer treatment drugs during the forecast period and which will have the highest CAGR?
• What are major companies developing metastatic cancer treatment drugs targeted for different therapeutic indication and what were sales of drugs for the past three years (2015-2017)?
• What are the drugs under developmental stages and the companies conducting their clinical study?

Market Overview

Cancer represents a major area of concern for the healthcare industry. It is one of the leading causes of deaths all around the world. According to World Health Organization (WHO), cancer claimed 8.8 million lives in 2015 and accounted for almost 1 in 6 global deaths. In low- and middle- income countries about 70% of deaths are caused due to cancer, depicting a significant burden on the global healthcare and economy. The total annual economic cost of cancer treatment was estimated approximately $1.16 trillion in 2010.

Metastatic cancer, also termed as stage IV (four) cancer, is the advanced form of cancer which spreads from its original tumor location to new sites of the body. Treatment of metastatic cancer is more complicated than early-staged cancer. Metastatic cancer is curable under certain situations, although most of the treatments are focused on providing palliative care. With increase in the prevalence of disease and increase in life expectancy, there is also a rise in the R&D expenditure in the field of oncology. Additionally, several biopharmaceutical companies are trying to enter the market and are investing into oncology field to meet the increasing treatment needs of the metastatic cancer patients. Such companies continue to endeavour for cost-effective oncology medicines with high productivity. Further, with the advent of precision medicine in the healthcare industry, there is an opportunity for the development of personalized cancer treatment drugs.

The global metastatic cancer treatment market was valued $54.11 billion in 2017, and is anticipated to reach $98.24 billion by 2025. Rising prevalence of cancer disease around the world and high unmet medical needs of patients suffering from metastatic cancer are the drivers stimulating the growth of the metastatic cancer treatment market. In addition, increasing adoption of biologics and biosimilars and ascending approvals from regulatory bodies, are contributing to the rising use of biologics for the treatment of metastatic cancer.

The purpose of the study is to gain a holistic view of the global metastatic cancer treatment market in terms of various factors influencing it such as key market trends, competitive and regulatory aspects of the market, scientific innovations into oncology fields, etc. The scope of the report is centered upon conducting a detailed study of the solutions allied with metastatic cancer treatment market, which involves drugs used in different therapeutic applications for cancer treatment such as chemotherapy, hormone therapy, and immunotherapy, among others. The global metastatic cancer treatment market is segmented into three different parts: ‘by products’, ‘by therapeutic indication’, and ‘by region’. The global market value for metastatic cancer was estimated using these three different approaches and was validated with one another. These segments are further segmented into several sub-segments to ease the market estimation.

Based on products, the market can be sub-segmented into branded medicines and generic medicines. The market for branded medicines, in terms of revenue, far exceeds the market of generic medicines. The growth of the branded medicine market is accredited to the rising demand for advanced oncology medicines along with increase in the research and development facilities globally. However, generic medicine market exhibits much higher growth rate due to the patent expiry of branded drugs and availability of cancer treatment drugs at an affordable price. The presence of the same active substance in generic drugs, which are as safe and effective as their brand-name counterparts is the major advantage of generic medicines.

Based on therapeutic indication, the market can be classified into six major cancer types, which include breast cancer, melanoma, lung cancer, prostate cancer, colorectal cancer, and others. Among the different types of cancers, breast cancer is the leading contributor of metastatic cancer treatment market, while the highest CAGR is registered by melanoma during the forecast period from 2018 to 2025.

Geographically, the market is sub-segmented into five distinct regions including, North America, Europe, Asia-Pacific, Latin America, and Rest of the World. North America, followed by Europe, is the leading contributor of the market. Within North America, the U.S. contributed for almost 95% of the total share, and the rest was occupied by Canada in 2017. Within Europe, Germany dominated the market in 2017. However, the market for Asia-pacific region is expected to demonstrate high growth rate, during the forecast period from 2018 to 2025, as compared to other regions, and the region holds a strong potential for market expansion in the future.

The metastatic cancer treatment market has a promising potential for growth in the coming years. The report provides an in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each company. The key players of the market are AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi and Takeda Pharmaceutical Company Limited, among others.